Innovation Pharmaceuticals Inc (IPIX)

[frrol]

I expect the secondary endpoints soon, and it is not a foregone conclusion they're bad (I know you didn't say that). I suspect they're in line with the top line, that is: good enough as a viable OM therapy, not spectacular. BP M&A teams would be less inclined to offer the moon, but they would be interested in a deal. B is proving to have commercially viable anti-inflammatory properties and I suspect we'll get a partnership deal.